Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia.

Megías-Vericat JE, Martínez-Cuadrón D, López JM, Bergua JM, Tormo M, Serrano J, González A, de Oteyza JP, Vives S, Vidriales B, Herrera P, Vera JA, Martínez AL, de la Fuente A, Amador ML, Hernández-Rivas JÁ, Fernández MÁ, Cerveró CJ, Morillo D, Campo PH, Gorrochategui J, Primo D, Rojas JL, Guenova M, Ballesteros J, Sanz M, Montesinos P.

Mediterr J Hematol Infect Dis. 2019 Mar 1;11(1):e2019016. doi: 10.4084/MJHID.2019.016. eCollection 2019.

2.

Preformed and induced mechanisms underlies the differential responses of Prunus rootstock to hypoxia.

Rubio-Cabetas MJ, Pons C, Bielsa B, Amador ML, Marti C, Granell A.

J Plant Physiol. 2018 Sep;228:134-149. doi: 10.1016/j.jplph.2018.06.004. Epub 2018 Jun 9.

3.

Physiological and biochemical parameters controlling waterlogging stress tolerance in Prunus before and after drainage.

Amador ML, Sancho S, Bielsa B, Gomez-Aparisi J, Rubio-Cabetas MJ.

Physiol Plant. 2012 Apr;144(4):357-68. doi: 10.1111/j.1399-3054.2012.01568.x. Epub 2012 Jan 28.

PMID:
22221115
4.

Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.

Barragán E, Montesinos P, Camos M, González M, Calasanz MJ, Román-Gómez J, Gómez-Casares MT, Ayala R, López J, Fuster Ó, Colomer D, Chillón C, Larrayoz MJ, Sánchez-Godoy P, González-Campos J, Manso F, Amador ML, Vellenga E, Lowenberg B, Sanz MA; PETHEMA; HOVON Groups.

Haematologica. 2011 Oct;96(10):1470-7. doi: 10.3324/haematol.2011.044933. Epub 2011 Jun 17.

5.

Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer.

Garrido-Laguna I, Amador ML, Ruiz J, Cortés-Funes H.

Clin Transl Oncol. 2009 Mar;11(3):183-5.

PMID:
19293057
6.

Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer.

Jimeno A, Rubio-Viqueira B, Amador ML, Grunwald V, Maitra A, Iacobuzio-Donahue C, Hidalgo M.

Mol Cancer Ther. 2007 Mar;6(3):1079-88.

7.

Assessment of celecoxib pharmacodynamics in pancreatic cancer.

Jimeno A, Amador ML, Kulesza P, Wang X, Rubio-Viqueira B, Zhang X, Chan A, Wheelhouse J, Kuramochi H, Tanaka K, Danenberg K, Messersmith WA, Almuete V, Hruban RH, Maitra A, Yeo CJ, Hidalgo M.

Mol Cancer Ther. 2006 Dec;5(12):3240-7.

8.

Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.

Jimeno A, Arcediano A, Bazares S, Amador ML, González-Cortijo L, Ciruelos E, Robles L, Castellano D, Paz-Ares L, Lumbreras C, Hornedo J, Cortés-Funes H.

Clin Transl Oncol. 2006 Dec;8(12):889-95.

PMID:
17169762
9.

An in vivo platform for translational drug development in pancreatic cancer.

Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, Tanaka K, Singh S, Salimi-Moosavi H, Bouraoud N, Amador ML, Altiok S, Kulesza P, Yeo C, Messersmith W, Eshleman J, Hruban RH, Maitra A, Hidalgo M.

Clin Cancer Res. 2006 Aug 1;12(15):4652-61.

10.

Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.

Hidalgo M, Amador ML, Jimeno A, Mezzadra H, Patel P, Chan A, Nielsen ME, Maitra A, Altiok S.

Mol Cancer Ther. 2006 Jul;5(7):1895-903.

11.

Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors.

Jimeno A, Daw NC, Amador ML, Cusatis G, Kulesza P, Krailo M, Ingle AM, Blaney SM, Adamson P, Hidalgo M; Children's Oncology Group.

Pediatr Blood Cancer. 2007 Sep;49(3):352-7.

PMID:
16425266
12.

Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Hitt R, Amador ML, Quintela-Fandino M, Jimeno A, del Val O, Hernando S, Cortes-Funes H.

Cancer. 2006 Jan 1;106(1):106-11.

13.

Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.

Jimeno A, Rubio-Viqueira B, Amador ML, Oppenheimer D, Bouraoud N, Kulesza P, Sebastiani V, Maitra A, Hidalgo M.

Cancer Res. 2005 Apr 15;65(8):3003-10.

14.

Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.

Hitt R, Ciruelos E, Amador ML, Benito A, Sanchez JJ, Ballestin C, Cortes-Funes H.

Eur J Cancer. 2005 Feb;41(3):453-60.

PMID:
15691646
15.

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

Amador ML, Oppenheimer D, Perea S, Maitra A, Cusatis G, Iacobuzio-Donahue C, Baker SD, Ashfaq R, Takimoto C, Forastiere A, Hidalgo M.

Cancer Res. 2004 Dec 15;64(24):9139-43. Erratum in: Cancer Res. 2007 Aug 15;67(16):7937. Cusati, George [corrected to Cusatis, George].

16.

Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer.

Amador ML, Hidalgo M.

Clin Colorectal Cancer. 2004 May;4(1):51-62. Review.

PMID:
15207021
17.

Dose and dose intensity effect of adjuvant anthracycline-based chemotherapy in early breast cancer: a retrospective analysis.

Amador ML, Jimeno A, Hitt R, Cortés-Funes H, Colomer R.

Am J Clin Oncol. 2004 Jun;27(3):269-73.

PMID:
15170146
18.

Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma.

Jimeno A, Amador ML, González-Cortijo L, Tornamira MV, Ropero S, Valentín V, Hornedo J, Cortés-Funes H, Colomer R.

Cancer. 2004 May 1;100(9):1833-42.

19.

Synthesis and antitumor evaluation of benzoylphenylurea analogs.

Gurulingappa H, Amador ML, Zhao M, Rudek MA, Hidalgo M, Khan SR.

Bioorg Med Chem Lett. 2004 May 3;14(9):2213-6.

PMID:
15081011
20.

Progress in the development and acquisition of anticancer agents from marine sources.

Amador ML, Jimeno J, Paz-Ares L, Cortes-Funes H, Hidalgo M.

Ann Oncol. 2003 Nov;14(11):1607-15. Review. No abstract available.

PMID:
14581267

Supplemental Content

Loading ...
Support Center